“I continue to expect our Structural Heart growth to be high single digits for the full year.”

In context

“etty well. In our queue, we have a reconciliation of the impact of moving those sales out of Structural Heart into EP—that is a big contributor to the disconnection between the street model and what we delivered. On top of that, we have seen some competitive intensity increase in the mitral space as one of our main competitors expanded their portfolio. My team can do a better job there; they know that. We need to improve our execution in the U.S. We have made some changes to leadership, and I am expecting our U.S. commercial team to respond to the challenge. Internationally, growth continues to be very strong across the entire portfolio, and we are delivering double-digit growth in Mitral, TriClip, and our Structural Interventions business. While there will be some geographic differences, I continue to expect our Structural Heart growth to be high single digits for the full year. We have a couple of trial readouts. We have completed enrollment in our Catalyst trial. I do not have a big reaction to my competitor's trial; I will wait until ours comes out and then comment. It is a high-growth, attractive business. Our next-generation product is very exciting, and moving it to our EP business should provide better acceleration for that product and allow our Structural Heart team to stay focused on valvular products. Matt Taylor: Thank you very much. Operator: Our next question will come from Travis Steed from BofA Securities. Your line is open. Travis Steed: Hey, everybody. I wanted to ask on the Nutrition business. I heard you mention that volume is starting to recover a bit. Any other color you can give on getting confidence in that business returning to growth in t”